Beyond the Scales: How Wegovy Is Now Saving Hearts — and What It Means for You

Last updated: 18 September 2026

Wegovy (semaglutide) is known as a weight-management medicine, but NICE now also recommends it for reducing the risk of major cardiovascular events in a specific group of adults. This article explains who that recommendation applies to and what it does not mean.

What has NICE recommended?

NICE technology appraisal TA1152 recommends semaglutide as an option for reducing the risk of major adverse cardiovascular events in adults who have established cardiovascular disease and are overweight or living with obesity. It is used alongside standard cardiovascular care, a reduced-calorie diet and increased physical activity.

The recommendation is specifically for secondary prevention: reducing the risk of a further serious cardiovascular event in people who already have cardiovascular disease. It is not a recommendation to use Wegovy to prevent heart disease in everyone who is overweight.

Who may be eligible?

To be considered under this NICE recommendation, a person must have established cardiovascular disease, such as a previous heart attack, stroke or symptomatic peripheral arterial disease, and a BMI of 27 kg/m² or above. A GP or specialist will assess whether treatment is suitable in the context of the person's full medical history and current treatment.

People are not automatically prescribed semaglutide because they meet the criteria. Individual assessment and local NHS pathways still apply.

What evidence supports the guidance?

NICE considered evidence from the SELECT trial, which studied adults with established cardiovascular disease and a BMI of at least 27 kg/m² who did not have diabetes. In that study, semaglutide plus standard care reduced the risk of a major cardiovascular event compared with placebo plus standard care.

Clinical-trial results describe the average effect in the people studied; they do not predict the result for any one person. Semaglutide is not a substitute for statins, blood-pressure treatment, smoking cessation, dietary changes or other cardiovascular care recommended by a clinician.

How can people access it on the NHS?

NICE guidance requires NHS funding for eligible people in England within 90 days of final publication. Local integrated care boards and clinical services determine how assessment and prescribing are delivered. If you think you may be eligible, speak to your GP or cardiovascular team about your individual circumstances and the local pathway.

What about Wegovy for weight management?

Wegovy also has a separate weight-management indication. The eligibility criteria and treatment pathway for that use are different from the cardiovascular recommendation. A qualified prescriber should assess which, if any, treatment approach is appropriate for you.

Safety and clinical advice

Semaglutide is a prescription-only medicine and is not suitable for everyone. Do not start, stop or change treatment without speaking to a healthcare professional. Tell your clinician about your medical history and other medicines, especially if you are pregnant, planning pregnancy or breastfeeding.

This article is for general information and is not medical advice. Prescription treatment is supplied only after a clinical assessment.

Sources

• NICE TA1152: Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity.
• NICE: semaglutide injection to help prevent heart attacks and strokes.
• NHS England: Wegovy to cut heart attack and stroke risk.

Last updated: 17 September 2026.